CRIS Current Research Information System

RICCIUTI, BIAGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.304
NA - Nord America 1.059
EU - Europa 517
SA - Sud America 150
AF - Africa 50
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.085
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 1.331
US - Stati Uniti d'America 1.025
SG - Singapore 710
CN - Cina 657
HK - Hong Kong 253
IT - Italia 146
BR - Brasile 114
KR - Corea 107
IN - India 77
NL - Olanda 62
DE - Germania 58
FI - Finlandia 44
IE - Irlanda 36
FR - Francia 32
JP - Giappone 28
SE - Svezia 25
BG - Bulgaria 23
JO - Giordania 22
AR - Argentina 20
TH - Thailandia 20
RU - Federazione Russa 19
AT - Austria 18
ID - Indonesia 18
MX - Messico 17
GB - Regno Unito 16
PH - Filippine 15
BD - Bangladesh 12
CA - Canada 11
CI - Costa d'Avorio 11
PK - Pakistan 10
IQ - Iraq 9
CH - Svizzera 7
TG - Togo 7
BE - Belgio 6
PL - Polonia 6
TR - Turchia 6
ZA - Sudafrica 6
LT - Lituania 5
VE - Venezuela 5
AU - Australia 4
MA - Marocco 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CL - Cile 3
EG - Egitto 3
GR - Grecia 3
IL - Israele 3
JM - Giamaica 3
KE - Kenya 3
MY - Malesia 3
PT - Portogallo 3
SC - Seychelles 3
UZ - Uzbekistan 3
DZ - Algeria 2
EC - Ecuador 2
ES - Italia 2
NP - Nepal 2
OM - Oman 2
PY - Paraguay 2
SA - Arabia Saudita 2
SN - Senegal 2
UY - Uruguay 2
AL - Albania 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
KZ - Kazakistan 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
PE - Perù 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.085
Salva come PNG Salva come JPEG
Città #
Singapore 463
Ho Chi Minh City 422
Hanoi 314
Hong Kong 248
Hefei 217
Ashburn 181
San Jose 171
Santa Clara 156
Seoul 97
Beijing 80
Boardman 60
Bologna 49
Da Nang 42
Haiphong 41
Helsinki 41
Dublin 36
Quận Bình Thạnh 32
Hyderabad 30
Los Angeles 27
New York 24
Ninh Bình 24
Biên Hòa 23
Buffalo 23
Sofia 23
Tokyo 23
Thái Nguyên 21
Amman 20
Bengaluru 20
Ha Long 19
Lauterbourg 19
Council Bluffs 18
Dallas 17
Can Tho 16
Hải Dương 16
Nuremberg 16
Falkenstein 14
Chandler 13
Redondo Beach 13
Shanghai 13
Bắc Ninh 12
Chicago 12
Rome 12
Seattle 12
Abidjan 11
Frankfurt am Main 11
Jakarta 11
Orem 11
Thành Phố Bà Rịa 11
Vinh 11
Guangzhou 10
Milan 10
Quận Phú Nhuận 10
San Francisco 10
São Paulo 10
Vũng Tàu 10
Điện Bàn 10
Bắc Giang 9
Mexico City 8
Thái Bình 8
Tongling 8
Vienna 8
Bangkok 7
Cà Mau 7
Lomé 7
Quảng Ngãi 7
Quận Bốn 7
Wuhan 7
Zhengzhou 7
Bern 6
Hòa Bình 6
Modena 6
Nam Định 6
Nanjing 6
Nha Trang 6
Quận Một 6
San Antonio 6
Turin 6
Uyen Hung 6
Valdagno di Trento 6
Amsterdam 5
Brasília 5
Brooklyn 5
Chengdu 5
Foshan 5
Mumbai 5
Phủ Lý 5
Quận Bảy 5
Shenzhen 5
The Dalles 5
Tianjin 5
Tuy Hoa 5
Việt Trì 5
Yubileyny 5
Atlanta 4
Baghdad 4
Bình Phước 4
Hangzhou 4
Houston 4
Indianapolis 4
Islamabad 4
Totale 3.520
Salva come PNG Salva come JPEG
Nome #
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 902
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 187
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 148
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels 146
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease 138
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 132
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks 130
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 130
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 124
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 120
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC 116
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 113
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 108
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 107
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 102
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 101
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 84
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 83
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 81
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 80
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 79
Non-small-cell lung cancer: how to manage RET-positive disease 77
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 74
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy 72
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) 69
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 68
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status 66
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 65
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 63
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 63
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis 63
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 62
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 60
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 58
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience 57
Non-small-cell lung cancer: how to manage EGFR-mutated disease 56
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 54
Antibody–drug conjugates for lung cancer in the era of personalized oncology 52
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 51
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation 51
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 47
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 47
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer 46
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient 46
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 42
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 41
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 40
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 39
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC 37
Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC 37
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 37
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) 37
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort 37
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 36
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 36
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 35
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer 34
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer 32
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 31
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 29
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 29
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 28
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 23
Totale 5.238
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.069
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.069
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202214 0 0 0 0 0 0 0 4 0 2 5 3
2022/2023204 3 8 0 9 7 4 3 14 73 34 20 29
2023/2024195 12 17 19 16 15 39 7 44 9 7 4 6
2024/20251.255 32 98 96 63 230 66 127 45 13 88 99 298
2025/20263.570 1.191 374 251 217 243 135 251 131 462 256 59 0
Totale 5.238